Clinical trials: Intestinal Neoplasms
Colorectal Cancer Stage III
A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer
This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-programmed cell death protein 1 (anti-PD1) antibody-activated autologous tumor-infiltrating lymphocytes (TILs)…
- Trial name
- NCT03904537
- Testing
- anti-PD-1 antibody-activated TILs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer (CRC)
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
The primary objective of this study is to evaluate the feasibility, safety, and efficacy of personalized T-cell therapy based on tumor neoantigens in patients with advanced colorectal cancer, so as to provide a novel…
- Trial name
- NCT07504523
- Testing
- iNeo-Vac-T01
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ying Yuan, MD
Colon Cancer Stage Iv
The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients
The purpose is to evaluate the effectiveness of high dose intravenous vitamin C (IVC) therapy plus very low carbohydrate diet (VLCD) for stage IV colon cancer (with KRAS and BRAF mutation ) with or without chemotherapy.
- Trial name
- NCT04035096
- Testing
- Ascorbic Acid, Control group
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy (CT), often requiring dose reductions or treatment interruptions, which can compromise efficacy of the planned CT…
- Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, Tingling
- Trial name
- OzoParQTmicrob (NCT06799351)
- Testing
- Ozone therapy
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Bernardino Clavo, MD, PhD
Locally Advanced Rectal Cancer (LARC)
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
In a single-center, prospective, phase II study (ClinicalTrials registration number: [to be filled in]) initiated by our center to evaluate the safety and preliminary efficacy of short-course radiotherapy followed by sequential…
- Trial name
- NCT07347951
- Testing
- Short-course radiotherapy, CAPOX chemotherapy, Targeted therapy with bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Colorectal Cancer, Photodynamic Diagnosis
The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics
This will be a pilot study involving 5 patients diagnosed with colorectal carcinoma and treated with pre-operative chemotherapy and external beam radiation therapy at the Jewish General Hospital, whom will very soon undergo…
- Trial name
- PDD (NCT03272659)
- Testing
- Cysview
- Sponsor
- Dr. Te Vuong
Colon Cancer
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected.
- Trial name
- NCT06301386
- Testing
- Everolimus, PD-1
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy.
- Trial name
- SPECTRA (NCT00958386)
- Testing
- Panitumumab+irinotecan
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Rectal Cancer
A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer
Rectal cancer is a common type of cancer and an important cause of illness and death worldwide. In 2020, cancers of the colon and rectum were the fourth most common cancers globally, and about one third of these cases were rectal…
- Trial name
- NCT07402486
- Testing
- Rectal HDR brachytherapy via Maastro Applicator
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Advanced Solid Tumor
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors.
- Trial name
- NCT06078670
- Testing
- CVL218
- Volunteers
- 96 people
- Sponsor
- Fujian Cancer Hospital
Anastomotic Leak Rectum, Rectal Cancer
Healing of Rectal Anastomosis Sealed With a Concentrate Derived From the Patient's Blood, After Rectal Cancer Surgery
Rectal cancer is one of the most frequent cancer diseases, with more than 1500 new cases per year in Denmark. Fortunately, if the tumor is discovered early, surgeons can remove the part of the intestine that is afflicted, and…
- Conditions
- Anastomotic Leak Rectum, Rectal Cancer, Anastomotic Leakage
- Trial name
- OBANORES (NCT05293054)
- Testing
- Application of autologous fibrin matrix (Obsidian)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Ovarian Cancer, Breast Cancer
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
- Trial name
- NCT05740956
- Testing
- HS-10502
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Colorectal Cancer
Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery
In this study, Investigator will compare mechanical bowel preparation with or without oral antibiotics in Left sided colorectal cancer patients undergoing elective surgery.
- Trial name
- NCT07429760
- Testing
- Rifampicin (R)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Shaukat Khanum Memorial Cancer Hospital & Research Centre
Ilues
Influence of Coffee Intake on Postoperative Bowel Function After Comprehensive Staging Surgery for Gynecological Malignancies: A Randomized Controlled Trial.
A delay in the return of normal bowel function with the passage of flatus and feces is one of the most important factors affecting early recovery and discharge in patients undergoing open complete staging surgery for…
- Trial name
- NCT01990482
- Testing
- caffe, Water
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Erzincan Military Hospital
ctDNA, Colorectal Cancer (CRC)
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with stage I or low-risk stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Colorectal Cancer (CRC), Adjuvant Chemotherapy
- Trial name
- CLEAR-01 (NCT07562659)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Inflammatory Bowel Diseases
Treatment Outcomes of Advanced Neoplasia in IBD
In this study, we aimed to (1) compare cumulative incidences of synchronous and metachronous colorectal neoplasia as well as mortality following AN in CD and UC patients who underwent proctocolectomy, (sub)total colectomy…
- Trial name
- NCT05674773
- Testing
- Endoscopic or surgical resection
- Where
- Netherlands
- Volunteers
- 189 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Neoplasm Malignant, Colon Cancer Stage 4
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC).
- Trial name
- NCT06575127
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Al-Azhar University
Colorectal Cancer
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer
Design: Prospective, randomized controlled trial Setting: Clinical Oncology and Nuclear Medicine, Ain Shams University Condition: Colorectal cancer Patients will be randomized into one of two groups: Group A: Patients will…
- Trial name
- NCT05921942
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Metastatic Colorectal Cancer
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA)…
- Trial name
- NCT00780169
- Testing
- sorafenib + FOLFIRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute